Anthem Biosciences Ltd.

748.70-18.3 (-2.39%)

8 Jul, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Anthem Biosciences Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M PR	12M PR	12M PR	12M PR	12M AR
Total Revenue	1,103	1,231	1,057	1,419	1,845	2,124
Cost of Operating Revenue	544	503	442	714	881	1,007
Gross Profit	560	728	615	706	963	1,118
Gross Margin	50.7	59.1	58.2	49.7	52.2	52.6
Total Operating Expenses	751	723	691	995	1,263	1,425
Operating Profit	352	508	366	425	582	700
Operating Margin	31.9	41.3	34.6	29.9	31.5	32.9
Financing Income/(Expense) - Net	-1	3	6	5	-3	51
Profit before Taxes	366	546	497	477	657	824
Income Taxes	94	141	112	110	206	232
Profit after Tax	271	406	385	367	451	592
PAT Margin	24.6	32.9	36.4	25.9	24.5	27.9
EPS - Basic - ex Extraordinary Items	4.83	7.22	6.86	6.54	8.04	10.55
EPS - Diluted - ex Extraordinary Items	4.83	7.22	6.86	6.54	8.04	10.43
EBIT	352	508	366	425	582	700
EBITDA	415	566	429	506	671	834
EBITDA Margin	37.6	46.0	40.6	35.7	36.4	39.3

Balance Sheet

Abridged

Understanding Balance Sheet

Anthem Biosciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	C 2025 Mar 31	2026 Mar 31

Source:	AR	PR	PR	PR	AR	AR
Total Current Assets	616	1,093	1,323	1,482	1,488	1,803
Long-Term Investments	3	7	11	18	272	508
Property Plant & Equipment - Net	374	476	604	821	998	1,047
Total Non-Current Assets	418	526	691	917	1,319	1,626
Total Assets	1,034	1,619	2,014	2,398	2,808	3,429
Total Current Liabilities	285	226	164	339	326	326
Long Term Debt	21	7	97	116	50	29
Total Non-Current Liabilities	47	38	110	135	71	61
Total Liabilities	332	264	274	473	398	387
Total Shareholders' Equity	700	1,353	1,741	1,925	2,410	3,043
Total Equity	701	1,355	1,741	1,925	2,410	3,043
Total Liabilities & Equity	1,034	1,619	2,014	2,398	2,808	3,429

Cash Flow

Abridged

Understanding Cash Flow Statement

Anthem Biosciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M PR	12M PR	12M PR	12M AR	12M AR
Operating CF bef Changes in Working Cap	355.89	471.30	432.03	433.48	626.27	777.44
Working Capital - Increase/(Decrease)	-94.46	-138.90	-103.63	-262.00	-300.69	139.42
Net CF from Operating Activities	261.42	332.40	328.40	171.48	325.58	916.86
Capital Expenditures - Net	87.12	160.68	193.77	296.49	263.31	205.84
Net CF from Investing Activities	-196.93	-215.03	-405.12	-262.32	-211.27	-780.89
Dividends Paid - Cash - Total	0.00	0.00	-	-	-	-
Stock - Issuance/(Retirement) - Net	7.59	247.50	-	-148.95	-	26.56
Debt - LT & ST - Issuance/(Retirement) - Total	-59.85	-64.52	89.57	107.46	-125.86	-59.69
Net Cash Flow from Financing Activities	-46.30	190.76	70.66	-67.65	-125.97	-33.10
Free Cash Flow to Equity	114.45	107.21	224.20	-17.55	-63.59	651.33
Free Operating CF net dividend	141.69	171.67	133.85	-125.71	60.00	705.69
Free Operating CF	141.69	171.67	133.85	-125.71	60.00	705.69

Business Segment Analysis

FY End:

Mar 26

Anthem Biosciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

CRDMO (83.4%)₹ 1,772.75 CrSpecialty Ingredients (16.6%)₹ 351.58 Cr

Regional Segment Analysis

FY End:

Mar 26

Anthem Biosciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Europe (53.9%)₹ 1,145.18 CrNorth America (27.3%)₹ 579.58 CrIndia (14.9%)₹ 315.79 CrRest of Asia and others (3.9%)₹ 83.78 Cr

Historical Segment Analysis

Track how Anthem Biosciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Business

Regional

Business

We don't have enough data to show the Capex for Anthem Biosciences Ltd..

Frequently Asked Questions

What is the revenue of Anthem Biosciences Ltd.?

The latest trailing twelve month revenue of Anthem Biosciences Ltd. is ₹ 2,124.33 Cr, reflecting a 1-year growth of 15.17% and a 3-year CAGR of 26.20%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Anthem Biosciences Ltd.?

The latest trailing twelve month net profit (PAT) of Anthem Biosciences Ltd. is ₹ 591.79 Cr, with a 3-year earnings CAGR of 15.00%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Anthem Biosciences Ltd.?

The trailing twelve month EBITDA of Anthem Biosciences Ltd. is approximately ₹ 699.74 Cr (based on an operating margin of 32.94%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Anthem Biosciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Anthem Biosciences Ltd. is 10.43. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Anthem Biosciences Ltd.?

The debt-to-equity ratio of Anthem Biosciences Ltd. stands at 0.02. The interest coverage ratio is 101.50x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Anthem Biosciences Ltd.?

The estimated book value per share of Anthem Biosciences Ltd. is 54.02 (derived from a P/B ratio of 13.86 and market price of ₹ 748.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Anthem Biosciences Ltd.?

The trailing twelve month operating cash flow of Anthem Biosciences Ltd. is ₹ 916.86 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Anthem Biosciences Ltd. report consolidated or standalone financials?

Anthem Biosciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.